Core Scientific, Inc./tx
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Operating Activities | ||||||
| Net Income | $-288.6M | $-1.44B | $-246.5M | $-2.15B | $47.3M | $-12.2M |
| Depreciation & Amortization | $68.9M | $113.2M | $96.0M | $225.3M | $33.4M | $9.4M |
| Depreciation | — | — | — | — | — | — |
| Amortization | — | — | — | $1.2M | $1.6M | — |
| Stock-Based Compensation | $98.2M | $51.9M | $58.9M | $182.9M | $38.9M | $3.0M |
| Net Cash from Operating Activities | $278.3M | $42.9M | $65.1M | $205.2M | $-56.7M | $-23.8M |
| Investing Activities | ||||||
| Capital Expenditures | $729.0M | $95.0M | $16.2M | $384.0M | $0 | $0 |
| Business Acquisitions | — | — | — | — | — | — |
| Net Cash from Investing Activities | $-740.8M | $-95.2M | $-3.0M | $-590.8M | $-423.8M | $-15.1M |
| Financing Activities | ||||||
| Dividends Paid | — | — | — | — | — | — |
| Stock Repurchases | — | $0 | $0 | $31.6M | — | — |
| Net Cash from Financing Activities | $-63.1M | $819.6M | $-44.6M | $306.2M | $603.5M | $40.7M |
| Net Change in Cash | $-525.6M | $767.3M | $17.5M | $-79.4M | $123.0M | $1.8M |
| Free Cash Flow | $-450.8M | $-52.1M | $49.0M | $-178.8M | $-56.7M | $-23.8M |